Latest News

Add to Favorites Subscribe Share
newswise-fb-share-
Embargo will expire:
20-Feb-2020 11:00 AM EST
Released to reporters:
19-Feb-2020 3:45 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 20-Feb-2020 11:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Novel targeted drug shows promise in advanced kidney cancer

Novel targeted drug shows promise in advanced kidney cancer

Dana-Farber Cancer Institute

Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease.

Channels: All Journal News, Cancer, Kidney Disease, Pharmaceuticals, Medical Meetings,

Released:
13-Feb-2020 12:45 PM EST
Open in New Tab
Comment
Research Results
DANA-FARBER-LOGO-JPG@4x.jpg

Dana-Farber Cancer Institute provides state-of-the-art oncology support services to Kronos employees through new company benefit

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute and Kronos Incorporated have joined forces to provide dedicated oncology care navigation services via a new benefit for Kronos employees and their beneficiaries.

Channels: Cancer, Healthcare, In the Workplace,

Released:
11-Feb-2020 10:00 AM EST
Open in New Tab
Comment
Research Results
Newswise: Dozens of potential anti-cancer drugs netted in massive screening study
  • Embargo expired:
    20-Jan-2020 11:00 AM EST

Dozens of potential anti-cancer drugs netted in massive screening study

Dana-Farber Cancer Institute

A variety of existing drugs for treating conditions such as diabetes, inflammation, alcohol abuse, and arthritis in dogs can also kill cancer cells in the lab, according to a study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Channels: All Journal News, Grant Funded News, Cancer, Clinical Trials, Pharmaceuticals, National Institutes of Health (NIH), Nature (journal),

Released:
19-Jan-2020 11:05 AM EST
Open in New Tab
Comment
Announcement
Newswise: Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative

Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.

Channels: Cancer, Family and Parenting, Healthcare, Grant Funded News,

Released:
13-Jan-2020 9:00 AM EST
Open in New Tab
Comment
Research Results
Newswise: Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers
  • Embargo expired:
    7-Jan-2020 9:00 AM EST

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer.

Channels: Cancer, Clinical Trials, Healthcare, In the Workplace, Respiratory Diseases and Disorders, Grant Funded News,

Released:
3-Jan-2020 3:55 PM EST
Open in New Tab
Comment
Announcement
Newswise: Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds
  • Embargo expired:
    9-Dec-2019 2:45 PM EST
Released:
26-Nov-2019 5:05 PM EST
Open in New Tab
Comment
Announcement
Newswise: Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting
  • Embargo expired:
    9-Dec-2019 7:45 AM EST

Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting

Dana-Farber Cancer Institute

Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.

Channels: Blood, Cancer, Cell Biology, Medical Meetings,

Released:
6-Dec-2019 8:30 AM EST
Open in New Tab
Comment
Research Results
Newswise: Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial
  • Embargo expired:
    7-Dec-2019 3:15 PM EST

Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial

Dana-Farber Cancer Institute

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

Channels: All Journal News, Cancer, Pharmaceuticals, Stem Cells, Transplantation,

Released:
5-Dec-2019 12:05 PM EST
Open in New Tab
Comment
Research Results
Newswise: Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows
  • Embargo expired:
    7-Dec-2019 8:45 AM EST

Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows

Dana-Farber Cancer Institute

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.

Channels: Blood, Cancer, Cell Biology, Medical Meetings,

Released:
6-Dec-2019 8:30 AM EST
Open in New Tab
Comment
Research Results


1.26905